Searches , social queries for ROUSSEL UCLAF
Search references for ROUSSEL UCLAF. Phrases containing ROUSSEL UCLAF
See searches and references containing ROUSSEL UCLAF!
Search references for ROUSSEL UCLAF. Phrases containing ROUSSEL UCLAF
See searches and references containing ROUSSEL UCLAF!ROUSSEL UCLAF
French pharmaceutical company
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical
Roussel_Uclaf
French businessman (born 1953)
Julien Gaston Roussel, who was President and General Manager of the Roussel Uclaf Laboratoires Pharmaceutiques, and his wife, Francine Grinda, daughter
Thierry_Roussel
French businessman
Paris. He later obtained an MBA at HEC Paris. In April 1986, he joined Roussel Uclaf (formerly France's second largest pharmaceutical company, until bought
Pascal_Soriot
Antiprogestogen and antiglucocorticoid drug
part of a formal research project at the French pharmaceutical company Roussel-Uclaf for the development of glucocorticoid receptor antagonists, endocrinologist
Mifepristone
Topics referred to by the same term
Asia Minor Roussel (automobile), a French automobile manufactured from 1908 to 1914 Roussel Uclaf, a French pharmaceutical company Big Roussel, the channel
Roussel
French multinational pharmaceutical and healthcare company
corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Cassella, Roussel Uclaf, and Marion Merrell Dow. Hoechst
Sanofi
German chemicals company
Merrell Dow of Kansas City, Missouri forming U.S. subsidiary Hoechst Marion Roussel (HMR). In 1997, Hoechst underwent a realignment wherein its various businesses
Hoechst_AG
Chemical compound
less sedative or muscle relaxant action. It was developed by a team at Roussel Uclaf in the 1990s Tully WR, Gardner CR, Gillespie RJ, Westwood R (July 1991)
Fasiplon
Chemical compound
nonsteroidal antiandrogen (NSAA) which was initially developed in the 1980s by Roussel Uclaf, the French pharmaceutical company from which it received its name.
RU-58841
mifepristone for personal use in 1989, a decision supported by Roussel Uclaf. In 1994, Roussel Uclaf gave the U.S. drug rights to the Population Council in exchange
Abortion_in_the_United_States
French pharmaceutical company
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Rhône-Poulenc
Thompson-Brandt. Partial nationalisation (51%+): Dassault, Honeywell-Bull, Matra, Roussel-Uclaf, Sacilor, Usinor. Thirty-nine banks, two financial houses, and the remaining
List of nationalizations by country
List_of_nationalizations_by_country
American anti-abortion organization
Choice Act, and announced a boycott of the French pharmaceutical company Roussel Uclaf and its American affiliates for permitting its abortion drug, mifepristone
National Right to Life Committee
National_Right_to_Life_Committee
US pharmaceutical company
& Company). Hoechst's new pharmaceutical company became Hoechst Marion Roussel and kept its North American headquarters in Kansas City. Hoechst in turn
Marion_Merrell_Dow
Benzodiazepine medication
Laboratories in Milan in the year 1969. Maestretti was acquired by Roussel Uclaf which became part of Sanofi. Internationally, clobazam is a federally
Clobazam
Chemical compound
Roxithromycin's half-life is 12 hours. French pharmaceutical company Roussel Uclaf first marketed roxithromycin in 1987. Fischer J, Ganellin CR (2006)
Roxithromycin
Rhône-Poulenc (1928–1999; merged with a Hoescht AG unit to form Aventis) Roussel Uclaf (1911–1997; acquired by Hoeschst AG) S. E. Massengill (1898–2011; acquired
List of pharmaceutical companies
List_of_pharmaceutical_companies
Chemical compound
assigned to Roussel-Uclaf GB 1024156, "Process for the preparation of 5-iodo-2'-desoxy-uridine", published 1966-03-30, assigned to Roussel-Uclaf Cheong
Idoxuridine
Japanese model (1936–2003)
Matsumoto married Jean-Claude Cathalan, who, at the time, was a manager at Roussel Uclaf. He later became the president of Revillon, Parfums Caron, Jean-Louis
Hiroko_Matsumoto
American healthcare product company
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Opella_North_America
French biochemist and endocrinologist (1926–2025)
Baulieu, who had identified the progesterone receptor, suggested to Roussel-Uclaf to modify the progesterone molecule to create an anti-progesterone.
Étienne-Émile_Baulieu
Chemical compound
sometimes in combination with ethinylestradiol. It was developed by Roussel Uclaf and has been registered for use only in France. Under the brand name
Norgestrienone
American research chemist (1899–1975)
from 1956. Merck and Roussel Uclaf concentrated on improving the production of corticosteroids from cattle bile acids. In 1960 Roussel produced almost one-third
Percy_Lavon_Julian
Month of 1982
pill", Mifepristone, development by the French pharmaceutical company Roussel-Uclaf and later called RU-486, was announced by the company at a press conference
April_1982
German-Canadian businessman (born 1960)
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Chris_Viehbacher
British pharmaceutical executive (born 1967)
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Paul_Hudson_(businessman)
Chemical compound
preparation]", published 1969-07-24, assigned to Roussel-Uclaf U.S. patent 3,644,368 Roussel Uclaf Mouzin G, Cousse H, Autin JM (1980). "A New, Convenient
Floctafenine
in the United States in 1979. In 1981, French pharmaceutical company Roussel-Uclaf developed the antiprogestogen mifepristone (also known as RU-486), which
History_of_abortion
Chemical compound
sold. The drug appears to have been an early development project of Roussel Uclaf, a French pharmaceutical company, and by the early 1970s, it was being
Trenbolone_acetate
Chemical compound
long-acting prodrug of trenbolone. The drug was described by researchers at Roussel Uclaf in 1967 and was the first long-lasting ester of trenbolone to be developed
Trenbolone_undecanoate
American pharmacologist
1990 UCLA School of Medicine Award for Excellence in Education. 1993 Roussel Uclaf Prize for Cell Communication and Signaling. Shared with Dr. Salvador
Louis_Ignarro
Drug class
anti-mineralocorticoids. The main active companies were Searle, Ciba-Geigy, Roussel Uclaf and Schering AG. Around 50 years after Selye's work, several pharmaceutical
Mineralocorticoid receptor antagonist
Mineralocorticoid_receptor_antagonist
Pharmaceutical manufacturer
misoprostol. Mifepristone was discovered in France in 1980 by scientists at Roussel-Uclaf, in a pharmaceutical program aimed at the identifying agents acting
Exelgyn
Biotechnology company
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Genzyme
Region of England
office of St Ivel; Patheon UK (pharmaceuticals, on the former site of Roussel Uclaf) are on the B4006 in Covingham, north of Valero, in the east of Swindon
South_West_England
Pharmaceutical compound
the other the bond is saturated. The secoergolines were obtained from Roussel-UCLAF in France, their properties were calculated, and their affinities for
RU-27251
Using drugs to bring about an abortion
in the United States in 1979. In 1981, French pharmaceutical company Roussel-Uclaf developed the antiprogestogen mifepristone (also known as RU-486). Mifepristone
Medical_abortion
Antibiotic to treat bacterial infections
Oflocet in France, Portugal, Tunisia, and several African countries by Roussel-Uclaf, as Oflocin by Glaxo in Italy, and as Flobacin by Sigma-Tau in Italy
Ofloxacin
Triangle Institute (mostly restricted to various phenyltropanes) RU – Roussel Uclaf RWJ – R. W. Johnson Pharmaceutical Research Institute, now part of Johnson
List of pharmaceutical compound number prefixes
List_of_pharmaceutical_compound_number_prefixes
Pharmaceutical drug
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Olipudase_alfa
Calendar year
hours after announcing it was abandoning RU-486, French manufacturer Roussel Uclaf states that it will resume distribution of the drug. October 29 – Pakistan's
1988
Chemical compound
the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed. It is a selective antagonist of the androgen
RU-22930
Combination drug
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Fexofenadine/pseudoephedrine
Birth control method taken orally
Searle 1970 1968 Norgestrienone Ethinylestradiol Planor Miniplanor Roussel Uclaf – – Norgestrel Ethinylestradiol Ovral Wyeth 1968 1972 Anagestone acetate
Combined oral contraceptive pill
Combined_oral_contraceptive_pill
German chemical and dye company
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Cassella
Pharmaceutical Research Centre in Northumberland
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Sterling-Winthrop Research Centre
Sterling-Winthrop_Research_Centre
Chemical compound
which are synthetic androgens/anabolic steroids. TMT was developed by Roussel Uclaf in France and was first known as early as 1969. It was one of the earliest
Trimethyltrienolone
Chemical compound
enamines and novel products", issued 20 September 1966, assigned to Roussel Uclaf SA Hesselink PG, van Vliet S, de Vries H, Witholt B (1989). "Optimization
Boldione
American feminist (1912–2005)
she had been a leader in the effort to get Paris-based manufacturer Roussel Uclaf to make the so-called "French abortion pill" (the "morning-after pill"
Molly_Yard
Medication
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Efanesoctocog_alfa
Chemical compound
JR, "Novel imidazobenzodiazepines", issued 1989-09-19, assigned to Roussel Uclaf Paul SM (May 2006). "Alcohol-sensitive GABA receptors and alcohol antagonists"
Ro15-4513
German journalist (born 1969)
universities of Cologne and Kent. In 1988, she completed an internship at Roussel Uclaf in Paris. Slomka lives in Cologne and Mainz. After university, Slomka
Marietta_Slomka
Chemical compound
RU-28362 is a synthetic androstane glucocorticoid that was developed by Roussel Uclaf. It is a selective agonist of the glucocorticoid receptor (corticoid
RU-28362
Chemical compound
was introduced for medical use in France in 1983. It was developed by Roussel Uclaf in France. Promegestone is the generic name of the drug and its INNTooltip
Promegestone
in 1998. Earlier testing had not occurred as the drug's developer, Roussel-Uclaf, had focused on Europe. An American NGO, Gynuity Health Project, also
Abortion_in_Tunisia
Swiss-French economist
Cossin worked for Goldman Sachs (London, UK) and pharmaceutical company Roussel-Uclaf (Tokyo, Japan). He was previously a Professor of Finance at HEC Lausanne
Didier_Cossin
French politician and lawyer
Federation (FHF). Évin is also notable for mandating the drug company Roussel Uclaf to resume the distribution of mifepristone, an abortifactant, two days
Claude_Évin
Chemical compound
almost the same as that of altrenogest). According to its manufacturer Roussel Uclaf, altrenogest has weak anabolic and androgenic activity equivalent to
Altrenogest
French scientist
collaboration with Gaston Roussel (1877-1947) at the Roussel-Uclaf laboratories, one of the forerunner companies of Sanofi. Roussel had trained as a veterinarian
Clotilde-Camille_Deflandre
French engineer and lobbyist
in 1984, Biot remained his advisor, up until 1985. Biot worked for Roussel Uclaf, a pharmaceutical company. He subsequently worked for Pasteur-Vaccins
Jacques_Biot
American pharmaceutical distributor
pharmaceutical company Exelgyn, under the trade name Mifegyne. On 16 May 1994, Roussel-Uclaf announced it was donating without remuneration all rights for medical
Danco_Laboratories
compound Structure Company Stage of development Other information RU58642 Roussel-Uclaf SA Preclinical – no further developments since 1998 Orally active and
Discovery and development of antiandrogens
Discovery_and_development_of_antiandrogens
French businessman (born 13 February 1956)
v t e Sanofi Predecessors Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow CEOs Chris Viehbacher Olivier Brandicourt Main products Cardiovascular
Olivier_Brandicourt
French official (1901–1990)
Financière Chimio in 1970, then chairman and chief executive officer of Roussel Uclaf from 1972 to 1977. Economy portal France portal %2F05%2F1901&size=n_60_n
Jacques_Brunet_(banker)
chloramphenicol first introduced by Roussel Uclaf in 1954; marketed as Tifomycine, it was originally used as a treatment for typhoid. Roussel stopped production of
International Dispensary Association Foundation
International_Dispensary_Association_Foundation
Chemical compound
was introduced for medical use in 1974 in France. It was developed by Roussel Uclaf. Demegestone is the generic name of the drug and its INNTooltip International
Demegestone
hours after announcing it was abandoning RU-486, French manufacturer Roussel Uclaf states that it would resume distribution of the drug, bowing to pressure
1988_in_France
travel, tourism, insurance
ROUSSEL UCLAF
ROUSSEL UCLAF
ROUSSEL UCLAF
ROUSSEL UCLAF
ROUSSEL UCLAF
ROUSSEL UCLAF
ROUSSEL UCLAF
ROUSSEL UCLAF
ROUSSEL UCLAF
travel, tourism, insurance